SANXING(SH:601567) Sou Hu Cai Jing·2025-08-23 20:52Core Viewpoint - Samsung Medical's stock price has decreased by 3.3% this week, closing at 23.41 yuan, with a total market capitalization of 32.897 billion yuan as of August 22, 2025 [1] Shareholder Changes - As of June 30, 2025, the number of shareholders increased by 12,600 to 29,000, representing a growth of 76.91% since March 31, 2025 [2][6] - The average number of shares held per shareholder decreased from 86,200 to 48,700, with an average holding value of 1.0926 million yuan [2] Performance Disclosure - For the first half of 2025, Samsung Medical reported a main revenue of 7.972 billion yuan, a year-on-year increase of 13.93% [3] - The net profit attributable to shareholders was 1.23 billion yuan, up 6.93% year-on-year, while the net profit excluding non-recurring items was 1.136 billion yuan, an increase of 5.34% [3] - In Q2 2025, the company achieved a main revenue of 4.341 billion yuan, a year-on-year increase of 9.28%, but the net profit attributable to shareholders decreased by 5.77% to 740 million yuan [3] - The company's debt ratio stands at 46.62%, with investment income of 119 million yuan and financial expenses of -115 million yuan, while the gross profit margin is 28.97% [3] Company Announcements - Samsung Medical announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 4.85 yuan per 10 shares (including tax) [4] - The total number of shares eligible for profit distribution is approximately 1.399 billion, with an expected total cash dividend of about 678.76 million yuan, accounting for 55.20% of the net profit attributable to shareholders for the first half of 2025 [4] - The profit distribution plan is subject to approval at the company's second extraordinary general meeting in 2025 and will not significantly impact the company's operating cash flow or long-term development [4]